Tyrosine Kinase Signaling in Cancer, Disease, & Development

癌症、疾病中的酪氨酸激酶信号传导，

• 批准号: 8398049
• 负责人: Cynthia K Miranti
• 金额: $ 0.8万
• 依托单位: FEDERATION OF AMER SOC FOR EXPER BIOLOGY
• 依托单位国家: 美国
• 财政年份: 2012
• 资助国家: 美国
• 起止时间: 2012-07-17 至 2013-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8398049
• 关键词: Achievement; Address; Area; Award; Biology; Biotechnology; Cancer Biology; Characteristics; Clinic; Collaborations; Degenerative Disorder; Development; Developmental Process; Discipline; Disease; Drug Delivery Systems; Drug Industry; Educational workshop; Financial Support; Funding; Future; Genomics; Goals; Human Genome; Immersion Investigative Technique; Industry; Knowledge; Lead; Link; Malignant - descriptor; Malignant Neoplasms; Maps; Medicine; Mutation; Outcome; Participant; Patients; Pharmacologic Substance; Protein Tyrosine Kinase; Regulation; Request for Applications; Research Personnel; Role; Scientist; Senior Scientist; Signal Transduction; Structure; Technology; Therapeutic; Translational Research; Translations; Travel; Work; abstracting; base; cancer cell; cancer therapy; combat; human disease; improved; interest; new technology; oncology; posters; prevent; programs; success; symposium; therapeutic development; therapeutic target

DESCRIPTION (provided by applicant): The original identification and linkage of tyrosine kinases to the development of malignant disease opened an entire new field in oncology. Continued proof of the importance and growing interest in tyrosine kinases in cancer continues unabated, as the successful therapeutic targeting of several tyrosine kinases in the clinic continues to expand both the discipline and the pharmaceutical industry. The complete sequencing of the human genome identified additional tyrosine kinases, many of which are still being characterized. The advent of high throughput sequencing and rapid genomic mapping have further advanced the importance of tyrosine kinases and their effectors in developmental, immunological, and degenerative diseases and spawned therapeutic development in these disciplines. This field defines the current and future state-of-the-art of targeted therapies and personalized medicine in cancer and is rapidly expanding to other areas. The challenges facing the field today are to improve our knowledge to develop better therapeutic strategies, to better understand what goes wrong when a therapy doesn't work, and bridge the gap between the scientists and the clinic. Support and retention of new young investigators in the field is of paramount importance for filling the gaps and over- coming these challenges. There are three specific objectives of the FASEB 2012 Tyrosine Kinase Signaling in Cancer, Development, and Disease Conference. The first objective is to disseminate and synthesize the most up-to-date knowledge and newest technologies surrounding tyrosine kinases, as it relates to structure, regulation, signaling mechanisms, impact on normal and cancer biology, and drug targeting. The goal is to under- stand how their mutation or aberrant expression leads to disease. This will be accomplished through keynote and plenary speakers, short presentations based on selected abstracts, question and answer sessions, poster sessions, and informal discussion. The second objective is to enhance interactions that promote collaboration and translational research to help bring new therapies to the clinic. The goal is to build the bridges between scientists and the technologies that are needed to lead to better therapeutics. This will be accomplished by, hosting an industry-sponsored workshop emphasizing translation. The third objective is to invest intellectually and financially in the future by supporting promising young trainees. The goal is to encourage trainees to be successful and stay in the field by providing intellectual support through discussions with senior scientists, poster sessions, opportunities to speak, awards that recognize their achievements, and by providing financial support with competitive travel awards. The expected outcomes are increased collaborations, retention of young scientists in the field, identification of new developmental processes and diseases linked to tyrosine kinase signaling, and exploration of new avenues and approaches for identifying and developing therapeutic tar- gets and strategies to combat cancer, developmental deficiencies, and other diseases. 1) continue the in-depth structural, functional, and mechanistic characterization of tyrosine kinases, their regulators, and downstream effectors, 2) understand how their mutation or aberrant expression leads to disease, 3) present the successes and controversies associated with therapeutic targeting of these molecules, 4) build the bridges between scientists and the technologies that are needed to lead to better therapeutics, and 5) support and encourage trainees to be successful and stay in the field. PUBLIC HEALTH RELEVANCE: This application requests funding to provide partial support of a conference focused on the roles of tyrosine kinases in normal biology and cancer. Tyrosine kinases are frequently abnormal in cancer cells and are the fundamental basis for the recent development of targeted-therapies and personalized medicine in cancer treatment. Participants at this conference will be exposed to the challenges and barriers of tyrosine kinase-based therapeutics, be provided with ideas on how to address them, and be encouraged to incorporate these ideas into their future research programs. Only through this kind of intense immersion and focus, that is characteristic of small conferences such as this one, can we hope to be successful at breaking down the barriers that prevent a 100% success rate for curing cancer and alleviating patient suffering.

描述（由申请人提供）：酪氨酸激酶与恶性疾病发展的最初鉴定和联系开辟了肿瘤学的一个全新领域。酪氨酸激酶在癌症中的重要性和日益增长的兴趣的持续证明继续有增无减，因为临床中几种酪氨酸激酶的成功治疗靶向继续扩展学科和制药工业。人类基因组的完整测序鉴定了其他酪氨酸激酶，其中许多仍在表征中。高通量测序和快速基因组作图的出现进一步推进了酪氨酸激酶及其效应物在发育、免疫和退行性疾病中的重要性，并在这些学科中产生了治疗发展。该领域定义了癌症靶向治疗和个性化医疗的当前和未来最新技术水平，并正在迅速扩展到其他领域。当今该领域面临的挑战是提高我们的知识以制定更好的治疗策略，更好地了解治疗不起作用时出现的问题，并弥合科学家和诊所之间的差距。支持和留住外地新的年轻调查员对于填补空白和克服这些挑战至关重要。FASEB 2012酪氨酸激酶信号传导在癌症，发展和疾病会议有三个具体目标。第一个目标是传播和综合围绕酪氨酸激酶的最新知识和最新技术，因为它涉及结构，调节，信号传导机制，对正常和癌症生物学的影响以及药物靶向。目的是了解它们的突变或异常表达是如何导致疾病的。这将通过主旨发言人和全体会议发言人、基于选定摘要的简短介绍、问答会议、海报会议和非正式讨论来实现。第二个目标是加强促进合作和转化研究的互动，以帮助将新疗法引入临床。我们的目标是在科学家和技术之间建立桥梁，以实现更好的治疗。这将通过主办一个强调翻译的行业赞助的研讨会来实现。第三个目标是通过支持有前途的年轻受训者，对未来进行智力和财政投资。目标是 鼓励受训人员取得成功并留在实地，为此提供智力支持，包括与资深科学家讨论、张贴海报、提供发言机会、颁发表彰其成就的奖项，以及提供具有竞争力的旅行奖等财政支持。预期的结果是增加合作，留住该领域的年轻科学家，识别与酪氨酸激酶信号相关的新的发育过程和疾病，探索新的途径和方法，以识别和开发治疗目标和策略，以对抗癌症，发育缺陷和其他疾病。 1)继续深入研究酪氨酸激酶的结构、功能和机制， 它们的调节子和下游效应子，2）了解它们的突变或异常表达如何导致疾病，3）展示与这些分子的治疗靶向相关的成功和争议，4）在科学家和技术之间建立桥梁，以获得更好的治疗方法，以及5）支持和鼓励受训者取得成功并留在该领域。 公共卫生相关性：该申请要求提供资金，以部分支持一个会议，重点是酪氨酸激酶在正常生物学和癌症中的作用。酪氨酸激酶在癌细胞中经常异常，并且是癌症治疗中靶向疗法和个体化药物的最新发展的基本基础。与会者将接触到酪氨酸激酶为基础的治疗的挑战和障碍，提供关于如何解决这些问题的想法，并鼓励将这些想法纳入他们未来的研究计划。只有通过这种强烈的沉浸和专注，这是小型会议的特点，我们才有希望成功地打破阻碍100%治愈癌症和减轻患者痛苦的障碍。